1 The eect of amylin on gastric ulcers induced by oral administration of indomethacin (Indo, 20 mg kg 71 at a dosing volume of 5 ml) or ethanol 50% (EtOH, 1 ml/rat) was investigated in conscious rats. 2 Amylin given intracerebroventricularly (0.22, 0.66 and 2.2 mg/rat, i.c.v.) demonstrated a dosedependent cytoprotective eect against both Indo and EtOH-induced ulcers. In contrast, amylin, given subcutaneously at doses eective in inhibiting acid gastric secretion (2.5, 10 and 40 mg kg 71 , s.c.), did not show any cytoprotective eect. 3 The interaction between amylin and endogenous nitric oxide (NO) in the maintenance of gastric mucosal integrity was investigated by pretreating the rats with a selective inhibitor of NO-synthesis, N Gnitro-L-arginine methyl ester (L-NAME, 25 and 70 mg kg 71 , s.c.). Administration of L-NAME to rats did not signi®cantly increase the degree of the Indo-induced ulcer index and was not able to remove the protective eect of amylin on Indo-induced ulcers, thus excluding a role for endogenous NO in mediating the protective eect of this peptide. 4 To determine whether the cytoprotective eect of amylin was mediated by endogenous prostaglandins, we studied the eect of amylin (2.2 mg/rat, i.c.v.) on EtOH-induced ulcers in rats pretreated with Indo (10 mg kg 71 , s.c.) to inhibit prostanoid biosynthesis; Indo was injected 30 min before amylin and EtOH after a further 30 min. Pretreatment with Indo did not signi®cantly increase the ulcer index induced by EtOH but counteracted the ability of amylin to prevent the ulcer formation. 5 These ®ndings suggest that amylin exerts a gastroprotective activity that is not strictly related to inhibition of acid gastric secretion and can be partly explained through a prostaglandin-dependent mechanism mediated by receptors for the peptide in the brain. Amylin might be considered as a new brain-gut peptide.
Introduction
Amylin is a 37-amino acid peptide isolated from pancreatic amyloid deposits in patients with non insulin-dependent diabetes mellitus (Cooper et al., 1987) as well as from human insulinoma (Westermark et al., 1987a) . The peptide is stored in the pancreatic B-cells and is secreted in response to the same stimuli that induce insulin release (Westermark et al., 1987b; Mitsukawa et al., 1990) . Unlike insulin, detectable amounts of amylin are found in extrapancreatic tissues including the lung, the central nervous system and the gut, from the stomach to the rectum (Toshimori et al., 1990; Miyazato et al., 1991) . Amylin mRNA is present in the stomach, in the lung and in the dorsal root ganglion (Ferrier et al., 1989) . The presence of amylin in the gastro-intestinal tract raises the possibility that the peptide has a functional role in this system. Very little is known so far concerning the role of amylin in gastric function. It has been found that the ingestion of food increases circulating levels of amylin (Butler et al., 1990) ; the administration of the peptide elicits anorectic eects (Morley et al., 1995) and inhibits acid gastric secretion (Guidobono et al., 1994) .
Amylin shares a 46% amino acid homology with calcitonin gene-related peptide (CGRP) (Cooper et al., 1987) and a weaker homology with salmon calcitonin (CT) (Pittner et al., 1994) . The three peptides have many activities in common and also show reciprocal cross-reactivity at their receptors, hence they are considered members of the same family of peptides (Poyner, 1995) .
Amongst the biological actions shared by amylin, CT and CGRP there are hypocalcaemic eects, inhibition of glucose incorporation into muscle glycogen (Leighton & Cooper, 1988; Datta et al., 1989) , inhibition of acid gastric secretion and food intake (Guidobono et al., 1990; Morley & Flood, 1991) , although the three peptides act with a dierent rank order of potency (Cooper, 1994) . Distinct receptors for amylin, CT and CGRP have been localized and characterized at both peripheral and central sites involved in the control of gastrointestinal functions (Sko®tsch et al., 1995; van Rossum et al., 1995) . However, it remains to be established whether or not amylin acts on its own receptors or through CT or CGRP receptors. Furthermore, it is not yet known whether amylin plays a role in the maintenance of gastric mucosal integrity and whether amylin antisecretory eect is relevant to this presumed activity. To characterize the potential gastroprotective activity of amylin, we evaluated the eect of central and peripheral administration of the peptide on gastric injury induced by indomethacin (Indo) or ethanol (EtOH), which are two types of ulcers dierently in¯uenced by CT and CGRP (Guidobono et al., 1991; Clementi et al., 1993) .
Methods

Animals
Male Sprague-Dawley rats, weight range 180 ± 200g (Charles River, Calco, Italy) were placed in single cages which had wirenet bottoms to prevent coprophagy. All experiments were performed in conscious animals that were deprived of food for 24 h but given free access to water until 30 min before the beginning of the experiments. Animals for i.c.v. studies were implanted with a polyethylene cannula (PE10) in the left lateral ventricle, 5 days before the experiment, as previously described (Guidobono et al., 1994) . , s.c. At the end of the experimental period the rats were anaesthetized with ether and the stomachs were dissected out and opened along the lesser curvature. Necrotizing lesions were examined macroscopically by 2 or 3 observers unaware of the treatment and lesions were classi®ed with arbitrary scales in which the severity rating and number of lesions were considered according to a modi®ed scoring system of Adami et al. (1964) ; 0=no lesions; 1=haemorrhagic suusion; 2=from 1 to 5 small ulcers 53 mm; 3=many ulcers, more than 5, or 1 ulcer of marked size; 4=many ulcers of marked size; 5=per-forated ulcers. For EtOH ulcers we used a modi®ed scoring system of Martin et al. (1994) ; 0=no lesions; 1=less than 5 slight lesions; 2=more than 5 slight lesions; 3=from 1 to 3 haemorrhagic bands of length 55 mm and width 42 mm; 4=from 1 to 3 haemorrhagic bands 45 mm in length; 6=complete lesions of the mucosa with haemorrhage. Mean scores for each group were calculated and expressed as the ulcer index.
Experimental procedures
In one group of experiments we used the inhibitor of nitric oxide-synthase activity, L-NAME, in order to investigate the role of endogenous nitric oxide (NO) on the protective eect of amylin on gastric erosions. L-NAME was administered at doses of 25 and 70 mg kg 71 , s.c. 15 min before amylin (0.66 mg/rat, i.c.v.) followed by Indo (20 mg kg 71 , orally) 5 min thereafter.
In another group of experiments Indo was administered s.c. (10 mg kg 71 ) to inhibit prostaglandin synthesis, amylin 2.2 mg/ rat, i.c.v. was administered after 30 min followed by EtOH 30 min later.
Having found that amylin was able to protect from gastric ulcers at doses previously found not to inhibit acid gastric secretion (Guidobono et al., 1994) , we repeated previous experiments on acid gastric secretion with the current batch of amylin and a wider range of doses.
Acid secretion studies These were performed by the pylorus ligation method (modi®ed from Shay et al., 1945) . Under light ether anaesthesia the pyloric sphincter was ligated through a small midline incision. The animals were killed 3 h later, stomachs were removed and the gastric content was collected. The volume of gastric juice was measured after centrifugation and the acid output was determined by titration with 0.01 N NaOH to pH 7.0. The experiments were repeated in order to have 7 ± 9 animals per group. Results are expressed as acid concentration in mEq of acid in 3 h (total volume) and presented as percentage of the mean of the controls. Amylin (0.22, 0.66, 1.5, 2.7 and 5 mg/rat, i.c.v.) or saline was given at the time of pyloric ligation.
Drugs
Rat amylin (Peptide Institute, Inc. Japan) for intracerebroventricular (i.c.v.) administration was dissolved in saline at concentrations suitable to be administered at 5 ml/rat; for subcutaneous (s.c.) injection amylin was dissolved in an appropriate diluent (1 g sodium acetate, 0.5 ml acetic acid, 0.1 g bovine serum albumin to 100 ml with double distilled water to give the ®nal dosing volume of 1 ml kg 71 ). Indomethacin (Indo, Sigma) for oral administration was suspended in arabic gum at a concentration of 20 mg kg 71 at a dosing volume of 5 ml; for s.c. injection. Indo was dissolved in NaHCO 3 5% and diluted in double distilled water and administered at a ®nal concentration of 10 mg kg 71 in a dosing volume of 1 ml. N G -nitro-L-arginine methyl ester (L-NAME, Tocris Cookson) was dissolved in saline to a concentration of 25 and 70 mg kg
71
, at a dosing volume of 1 ml, which are the doses used by Clementi et al. (1994) to inhibit NO formation in rats in an experimental model of ulcer. The doses used were far higher than those needed to evoke a rise of mean arterial blood pressure in rats (Holzer et al., 1993) . Ethanol (EtOH, BDH) was diluted to 50% in double distilled water and was given in a volume of 1 ml/rat. In all the experiments groups consisted of 5 ± 10 rats and control rats were treated with the vehicles used for the preparation of the drugs.
Statistical analysis
Data from pooled experiments were analysed by one way analysis of variance followed by Bonferroni tests. P50.05 was considered signi®cant. The dose-response curve and the linear regression analysis were performed by use of a statistic computer programme (Tallarida & Murray, 1981) .
Results
The eects of amylin on gastric ulcers are shown in Figure 1 . The peptide exhibited a protective eect in rats against Indoinduced ulcers in a dose-dependent manner (r=70.45, P50.01) with a range of doses between 0.22 and 2.2 mg/rat, i.c.v. Amylin was eective in protecting from Indo-induced ulcers at a dose of 0.66 mg/rat, i.c.v. (Figure 1 ). Under our experimental conditions, this was the minimal eective dose in inhibiting acid gastric secretion although gastric secretion volume and acidity were still substantial, being, respectively, 4.06+0.29 ml and 113.3+5.8 mEq ml with a dierent batch of the peptide where amylin was eective only from 1.5 mg/rat, i.c.v. (Guidobono et al., 1994) .
The s.c. administration of amylin at doses of 10 and 40 mg kg 71 was not able to prevent gastric erosions induced by Indo; no signi®cant eects were seen with these doses ( Figure  3 ). Higher doses were not used because data obtained previously on inhibition of acid gastric secretion showed that amylin 100 mg kg 71 , s.c., was less eective than 40 mg kg 71 , s.c. and the dose of 160 mg kg 71 , s.c. was completely ineective; a typical bell-shaped curve was obtained, as often seen with peptides (Guidobono et al., 1994) .
We considered the possibility that amylin might exert its protective eect on ulcers by increasing blood¯ow since it is well known that amylin, like CGRP, causes vasodilatation (Brain et al., 1990 ). As one of the possible endogenous factors responsible for such vasoactivity is NO, we examined the eect , orally) in rats pretreated with L-NAME 30 min before amylin. Data are expressed as mean+s.e.mean of 6 ± 8 animals. Solid columns, Indo; cross-hatched columns, Indo+L-NAME; stippled column, Amylin+Indo; open columns, L-NAME+Amylin+Indo. {P50.05 vs Indo, *P50.05 vs Indo+L-NAME treated group. of amylin on Indo-induced ulcers in rats pretreated with L-NAME, an inhibitor of NO-synthase. As shown in Figure 4 , L-NAME did not signi®cantly increase the extent of Indo-induced gastric ulceration. In rats pretreated with L-NAME, 25 and 70 mg kg 71 , amylin 0.66 mg/rat, i.c.v., was still able to protect from Indo-induced ulcers, thus excluding the possibility that the antiulcer eect of amylin is mediated by NO production.
Amylin at doses of 0.66 and 2.2 mg/rat, i.c.v., was also effective in preventing gastric damage induced by EtOH ( Figure  5) . The s.c. administration of amylin, 10 and 40 mg kg 71 , did not protect rats from gastric lesions induced by EtOH (data not shown). Figure 6 presents the results of the experiments performed to examine whether or not endogenous prostaglandins are involved in the protective eect of amylin on EtOH-induced gastric ulcers. Pretreatment with Indo, 10 mg kg 71 , s.c. did not increase the ulcer index compared to that in EtOH-treated animals but the protective eect of amylin on EtOH-induced ulcers was signi®cantly inhibited compared to the eect of amylin alone (ie amylin+EtOH group).
Discussion
We have demonstrated that amylin is able to protect against gastric ulcers induced by Indo or by EtOH. The antiulcer activity of i.c.v. administered amylin is evident when gastric acid secretion is signi®cantly reduced by 40%, yet acid secretion is still substantial compared to controls. Amylin injected s.c., at doses previously shown to be eective in reducing gastric acid secretion by 66.5% (Guidobono et al., 1994) , was not able to protect from gastric ulcers induced by Indo or by EtOH. These data thus emphasize that gastric protection by amylin involves mechanisms other than inhibition or neutralization of gastric acid secretion, in contrast with the classical antisecretory drugs, H + -K + -ATPase inhibitors, antimuscarinic and H 2 receptor antagonists whose anti-gastric ulcer and antisecretory eects go in parallel (Kromer et al., 1990) . The present ®ndings show that the administration of L-NAME did not prevent the protective eect of amylin on Indo-induced gastric erosion. However, pretreatment with Indo to block production of prostanoids, reduced the protective eect of amylin on EtOHinduced ulcers, indicating that prostanoids could, at least in part, be involved in this eect of amylin, as cytoprotection by prostaglandins is unrelated to the inhibition of gastric acid secretion (Robert et al., 1979) .
The data obtained in this study rule out the possibility that the vasodilating eect of NO contributes to the antiulcer activity of amylin, in contrast with results obtained with CGRP whose antiulcer eect involving the gastric microcirculation, is inhibited by blockade of NO synthesis (Clementi et al., 1994; Holzer et al., 1995) . Since the vascular eect of amylin is mediated by CGRP receptors (Beaumont et al., 1995) these ®ndings suggest that the cellular mechanisms subserving the ulcer protective eects of amylin and CGRP are dierent.
The dierence between amylin and CGRP is con®rmed by the protective eect of amylin on EtOH-induced gastric lesions as neither CGRP (Evangelista et al., 1987; Evangelista & Maggi, 1991) nor CT (Guidobono et al., 1991) are eective against EtOH-induced ulcers. These results again imply that amylin acts through its own receptor and not through interaction with the receptors for CGRP or CT and that the three peptides have dierent functional activities. The mechanisms of mucosal protection by amylin remain to be explored. The present ®ndings support the hypothesis that endogenous prostaglandins or prostacyclin contribute to the eect of amylin not only by exerting a local vasodilator action on the microcirculation but also by acting to enhance the gastric mucosal barrier.
Despite the fact that speci®c binding sites for amylin are present in the rat stomach (Bhogal et al., 1992) , the peptide administered s.c. did not show a cytoprotective eect, in contrast to CT and CGRP which are able to prevent gastric ulceration when injected peripherally (Guidobono et al., 1991; Clementi et al., 1993) . These dierences support the concept of the existence of distinct receptors in the stomach linked to dierent functions for the homologous peptides CT, CGRP and amylin. It would appear that the cytoprotective eect of amylin is mediated by speci®c receptors for the peptide in the brain. Recently it has been shown that amylin and its binding sites are widely distributed in the central nervous system (Sko®tsch et al., 1995; van Rossum et al., 1995) . Amylin and its binding sites have been shown to be present in other brain regions, in areas involved in gastric functions like the amygdala and the hypothalamus (lateral, arcuate, dorsomedial and paraventricular nuclei), so it is possible that the peptide has a role in the central control of gastric function, as suggested by the results presented here. Studies on the hypothalamic control of gastric function have shown the presence of glucose-sensitive neurones that are believed to be implicated in feeding and other gastric related activities. These glucose responding neurones are supposed to receive information from the gastrointestinal tract through vagal aerents to the nucleus of the solitary tract that functions as a relay centre between the periphery, the medulla oblongata and the hypothalamus (Shiraishi, 1988) .
Amylin has a well recognized role in glucose metabolism: the peptide activates glycogen phosphorylase and inhibits glycogen synthase (Young et al., 1990; Deems et al., 1991) , stimulates glycogen breakdown to lactate and increases glucose production (Rink et al., 1993) . In addition a marked reduction of blood glucose, as induced by insulin, can have a permissive role in the formation of gastric lesions even without signi®cant changes in acid secretion (Takeuchi et al., 1994) . Based on these facts, we propose that amylin could have a role in the central glucoregulation as a metabolic partner to insulin and as such would oppose the eect of insulin hypoglycaemia on gastric functions. It is possible that amylin by acting in the CNS triggers mechanisms leading in the periphery to the stimulation of a local neuromodulator that regulates the mucosal resistance. Amylin by means of the vagus, might activate the release of neuropeptides contained in sensory ®bres thus indirectly exerting a mucosal protective eect. In conclusion, although the role of this peptide in gastrointestinal function remains to be elucidated, it would seem that amylin should be included in the big family of brain-gut peptides.
